Insider Trading
| DNTH Stock | 18.29 1.12 5.77% |
Under 61% of Dianthus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dianthus Therapeutics suggests that many traders are alarmed. Dianthus Therapeutics' investing sentiment shows overall attitude of investors towards Dianthus Therapeutics.
Dianthus |
Filed transaction by Dianthus Therapeutics Executive. Insider Public Trading
Read at macroaxis.com
Dianthus Therapeutics Fundamental Analysis
We analyze Dianthus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Dianthus Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Dianthus Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dianthus Therapeutics stock to make a market-neutral strategy. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics with similar companies.
Peers
Dianthus Therapeutics Related Equities
| NOW | ServiceNow | 1.37 | ||||
| PKE | Park Electrochemical | 0.65 | ||||
| DOW | Dow | 0.33 | ||||
| ECVT | Ecovyst | 0.47 | ||||
| CC | Chemours | 2.08 | ||||
| TSE | Trinseo SA | 3.22 | ||||
| XFABF | X-FAB Silicon | 3.80 |
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |